ASX:4DX

4DMedical (4DX) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
4DX stock logo

About 4DMedical Stock (ASX:4DX)

4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lungs ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent 200, a small animal ventilator. The company was incorporated in 2012 and is based in Carlton, Australia.

4DX Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
4DMedical Limited (ASX:4DX): Is Breakeven Near?
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
4DMedical Limited (4DX.AX)
See More Headlines
Receive 4DX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4DMedical and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
131
Year Founded
N/A

Profitability

Net Income
$-30,830,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.03 million
Book Value
A$0.23 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.31
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Andreas Fouras M.A.I.C.D.
    Ph.D., Founder, MD, CEO & Director
  • Mr. Simon Glover
    Chief Financial Officer
  • Mr. John Andrew Livingston BAppSci
    GradCertBus, GradDipHSc, Executive Director
  • Ms. Naomi Lawrie
    Company Secretary & General Counsel
  • Ms. Rachael Tenkaten
    Chief of Staff
  • Dr. Aidan Jamison B.E.
    Ph.D., Senior Vice President of Engineering
  • Dr. Michael Curtis Ph.D.
    Chief Software Architect
  • Dr. Jon Dusting Ph.D.
    Chief Research Officer
  • Dr. Jason Kirkness Ph.D.
    Senior Vice President of Medical & Clinical Affairs
  • Mr. Matt Tucker
    Chief Commercial Officer

This page (ASX:4DX) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners